Correction: COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants (Annals of Intensive Care, (2024), 14, 1, (65), 10.1186/s13613-024-01296-0)

Following publication of the original article [1], the authors identified an error in Tables 1 and 2. In Table 1, the data for the “Sex, females” under the heading of “CAPA patients, n = 29” should be 8 (28) not 5 (28). The correct Table 1 is given in this correction. (Table presented.) Patient’s characteristics at the time of their admission to the intensive care unit according to the CAPA status Variable n/n All patients, n = 566 Non-CAPA patients, n = 537 CAPA patients, n = 29 p Demographics and comorbidities Sex, females 191 (34) 183 (34) 8 (28) 0.5 Age, years 66 [57–74] 66 [57–74] 67 [60–70] 0.7 Diabetes 179 (33) 168 (33) 11 (39) 0.5 Obesity 183 (33) 172 (32) 11 (38) 0.5 Chronic heart failure 52 (10) 52 (10) 0 0.1 Hypertension 281 (52) 266 (52) 15 (54) 0.8 Chronic respiratory failure 78 (14) 75 (15) 3 (11) 0.8 Chronic renal failure 113 (21) 107 (21) 6 (21) 0.9 Cirrhosis 8 (1) 7 (1) 1 (4) 0.3 Immunosuppression 189 (35) 174 (34) 15 (54) None 357 (65) 344 (66) 13 (46) 0.09 Solid organ transplant 67 (12) 63 (12) 4 (14) Onco-hematological malignancies 59 (11) 54 (10) 5 (18) Others 62 (11) 56 (11) 6 (21) Number of comorbidities 518/28 2 [1–3] 2 [1–3] 2 [1–4] 0.5 Clinical frailty scale 528/29 3 [2–4] 3 [2–4] 3 [2–4] 0.9 SARS-CoV-2 infection and vaccination Previous SARS-CoV-2 infection 506/28 40 (7) 39 (8) 1 (4) 0.8 SARS-CoV-2 vaccination 326 (59) 306 (59) 20 (69) 0.3 SARS-CoV-2 serology at ICU admission Unavailable 279 (49) 271 (50) 8 (28) Negative 129 (23) 119 (22) 10 (34) Positive 158 (28) 147 (27) 11 (38) First symptoms-ICU admission, days 535/29 7 [3–10] 7 [3–10] 8 [6–11] SARS-CoV-2 RNA detection in nasopharyngeal swabs, Ct 359/17 21 [18–25] 21 [18–25] 23 [20–26] 0.2 SARS-CoV-2 variant 387/24 Omicron 313 (76.2) 298 (77) 15 (62.5) 0.1 Delta 98 (23.8) 89 (23) 9 (37.5) Patients severity upon ICU admission and biological features WHO 10-point scale 353/29 6 [6–6] 6 [6–6] 6 [6–8] 0.09 SAPS II score 486/28 35 [27–45] 35 [27–44] 39 [26–53] 0.1 SOFA score 505/28 4 [3–6] 4 [3–6] 4 [3–8] 0.3 PaO/FiO ratio, mmHg 520/28 124 [79–188] 124 [79–190] 127 [76–170] 0.5 Arterial lactate level, mM 506/27 1.5 [1–2.2] 1.5 [1–2.3] 1.9 [1.1–2.2] 0.6 Blood leukocytes, G/L 529/29 8.9 [5.6–13] 8.9 [5.7–13] 3.9 [6.5–12.4] 0.2 Blood lymphocytes, G/L 434/26 0.5 [0.3–0.9] 0.5 [0.3–0.9] 0.4 [0.5–0.9] 0.9 Blood platelets, G/L 529/29 206 [146–298] 207 [148–289] 191 [107–315] 0.5 Serum urea level, mM 523/29 8 [6–15] 8 [5–14] 12 [7–18] 0.06 Serum creatinine level, µM 532/29 89 [63–141] 89 [62–138] 97 [73–235] 0.1 Lung parenchyma involvement, % 274/18 50 [37–75] 50 [37–75] 50 [40–70] 1 Oxygen/ventilatory support 0.2 Oxygen 100 (18) 97 (18) 3 (10) High flow oxygen 269 (48) 255 (48) 14 (48) NIV/C-PAP 58 (10) 57 (11) 1 (3) Invasive MV 135 (24) 124 (23) 11 (38) ECMO 15 (3) 15 (3) 0 1 Vasopressor support 86 (15) 82 (16) 4 (14) 0.8 Results are N (%), means (± standard deviation) or medians (interquartile range, i.e., quartile 1; quartile 3) CAPA COVID-19-associated pulmonary aspergillosis, ICU intensive care unit, Ct cycle threshold, WHO World Health Organization, SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology Score II, NIV non-invasive ventilation, C-PAP continuous-positive airway pressure, MV mechanical ventilation, ECMO extracorporeal mechanical ventilation Two-tailed p-values come from unadjusted comparisons using Chi-square or Fisher’s exact tests for categorical variables, and t-tests or Mann–Whitney tests for continuous variables, as appropriate. No adjustment for multiple comparisons was performed. Bolded p-values are significant at the p < 0.05 level Numbers of non-CAPA/CAPA patients data available Includes HIV infection, long-term corticosteroid treatment, and other immunosuppressive treatments Defined as < 30 Binding Antibody Units (BAU)/mL In Table 2, the data for Duration of vasopressors, days under the heading of variable has been corrected in this correction and the complete Table 2 is given in this correction. (Table presented.) Management and outcomes of patients with severe SARS-CoV-2 infection during their intensive care unit stay according to the CAPA status Variable n/n All patients, n = 566 Non-CAPA patients, n = 537 CAPA patients, n = 29 p Invasive MV 242 (43) 220 (41) 22 (76) Prone positioning 171 (32) 153 (30) 18 (64) MV duration, days 207/21 12 [5–22] 10 [5–20] 28 [17–34] Ventilator-free days at D28 25 [0–28] 26 [0–28] 0 [0–15] ECMO support 32 (6) 29 (5) 3 (10) 0.2 Duration of ECMO, days 25/3 27 [10–55] 29 [10–62] 19 [15–20] 0.4 Vasopressor support 218 (39) 197 (37) 21 (72) Duration of vasopressors, days 192/20 4 [1–12] 4 [1–10] 16 [9–30] Renal replacement therapy 69 (12) 60 (11) 9 (31) Ventilator-acquired pneumonia (among IMV) 126 (52) 108 (49) 18 (82) Time from IMV to VAP first episode, days 6 [2–10] 6 [2–9] 11 [6–20] Number of VAP episodes Median (IQR) 1 [0–1] 1 [0–1] 1 [1–2] 0 116 (48) 112 (51) 4 (18) 1 66 (27) 56 (26) 10 (45) 2 40 (17) 35 (16) 5 (23) 3 19 (8) 16 (7) 3 (14) Dexamethasone 415 (83) 392 (83) 23 (82) 0.9 Tocilizumab 165 (33) 156 (33) 9 (33) 0.9 Monoclonal antibodies 74 (15) 67 (14) 7 (25) 0.1 Day-28 mortality 161 (29) 151 (29) 10 (34) 0.5 Duration of ICU stay, days 522/29 9 [4–18] 8 [4–17] 28 [16–44] Results are N (%), means (± standard deviation) or medians (interquartile range, i.e., quartile 1; quartile 3) CAPA COVID-19-associated pulmonary aspergillosis, MV mechanical ventilation, ECMO extracorporeal membrane oxygenation, VAP ventilator-acquired pneumonia, IMV invasive mechanical ventilation Two-tailed p-values come from unadjusted comparisons using Chi-square or Fisher’s exact tests for categorical variables, and t-tests or Mann–Whitney tests for continuous variables, as appropriate. No adjustment for multiple comparisons was performed. Bolded p-values are significant at the p < 0.05 level Numbers of non-CAPA/CAPA patients data available VAP episodes were recorded per definition in patients under IMV since more than 48 h The correct Table 2 is given in this correction. In this article, the legend for Fig. 3 was incorrectly published. Incorrect legend of Fig. 3: Fig. 3 Unsupervised analysis of the clinical and biological characteristics of the by self-organized maps (SOMs). Unsupervised analysis by SOM automatically located patients with similar clinical and paraclinical parameters within 1 of 40 small groupings (“districts”) throughout the map. The more similar the patients, the closer on the map. Each individual map shows the mean values or proportions per district for each characteristic: blue indicates the lowest average values, red the highest, with numbers shown for a selection of representative districts in each SOM. For instance, immunosuppressed patients were more frequently located in the upper districts and also had higher serum urea levels, less frequent Delta variant infection, higher SAPS II and SOFA scores and day-28 mortality rates. WHO World Health Organization, SOFA Sequential Organ Failure Assessment, SAPS II Simplifed Acute Physiology Score II, MV mechanical ventilation Correct legend of Fig. 3: Fig. 3 Unsupervised analysis of the clinical and biological characteristics of the 566 critically-ill COVID-19 patients by self-organized maps (SOMs). Unsupervised analysis by SOM automatically located patients with similar clinical and paraclinical parameters within 1 of 40 small groupings (“districts”) throughout the map. The more similar the patients, the closer on the map. Each individual map shows the mean values or proportions per district for each characteristic: blue indicates the lowest average values, red the highest, with numbers shown for a selection of representative districts in each SOM. For instance, immunosuppressed patients were more frequently located in the upper districts and also had higher serum urea levels, less frequent Delta variant infection, higher SAPS II and SOFA scores and day-28 mortality rates. WHO World Health Organization, SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology Score II, MV mechanical ventilation The original article has been corrected.